Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cyclophosphamide treatment in active multiple sclerosis.
Gómez-Figueroa E, Gutierrez-Lanz E, Alvarado-Bolaños A, Casallas-Vanegas A, Garcia-Estrada C, Zabala-Angeles I, Cadena-Fernandez A, Veronica RA, Irene TF, Flores-Rivera J. Gómez-Figueroa E, et al. Among authors: zabala angeles i. Neurol Sci. 2021 Sep;42(9):3775-3780. doi: 10.1007/s10072-021-05052-1. Epub 2021 Jan 16. Neurol Sci. 2021. PMID: 33452657
Socioeconomic status and access to multiple sclerosis treatment in Mexico.
Gómez-Figueroa E, de Saráchaga AJ, García-Estrada C, Casallas-Vanegas A, Delgado-García G, Garcia-Martinez P, Zabala-Angeles I, Marcin-Sierra M, Moreno-Torres P, Corona-Vázquez T, Rivas-Alonso V, Flores-Rivera J. Gómez-Figueroa E, et al. Among authors: zabala angeles i. Mult Scler Relat Disord. 2021 Jul;52:102967. doi: 10.1016/j.msard.2021.102967. Epub 2021 Apr 20. Mult Scler Relat Disord. 2021. PMID: 33934010
Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in México.
Casallas-Vanegas A, Gomez-Figueroa E, de Saráchaga AJ, Zabala-Angeles I, García-Estrada C, Salado-Burbano JC, DiazGranados-Palacio MC, Corona-Vázquez T, de Jesús Flores-Rivera J, Rivas-Alonso V. Casallas-Vanegas A, et al. Among authors: zabala angeles i. J Neurol Sci. 2020 Dec 15;419:117204. doi: 10.1016/j.jns.2020.117204. Epub 2020 Oct 22. J Neurol Sci. 2020. PMID: 33161302
Clinical experience of plasmapheresis for neuromyelitis optica patients in Mexico.
Gómez-Figueroa E, Alvarado-Bolaños A, García-Estrada C, Zabala-Ángeles I, Sánchez-Rosales N, Bribiesca-Contreras E, García-Alvarez G, Montes-Pérez Y, Ramos-Vega E, Casallas-Vanegas A, Carrillo-Loza K, Corona-Vázquez T, Rivas-Alonso V, Flores-Rivera J. Gómez-Figueroa E, et al. Among authors: zabala angeles i. Mult Scler Relat Disord. 2021 Jul;52:103022. doi: 10.1016/j.msard.2021.103022. Epub 2021 May 15. Mult Scler Relat Disord. 2021. PMID: 34034213
Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder.
Gomez-Figueroa E, Noriega-Morales G, Casallas-Vanegas A, Zabala-Angeles I, Garcia-Estrada C, Neri D, Sarachaga AJ, Rivas-Alonso V, Corona-Vazquez T, Flores-Rivera J. Gomez-Figueroa E, et al. Among authors: zabala angeles i. Clin Neurol Neurosurg. 2020 Sep;196:106007. doi: 10.1016/j.clineuro.2020.106007. Epub 2020 Jun 9. Clin Neurol Neurosurg. 2020. PMID: 32559706
Rituximab as an effective therapeutic option in refractory Neuro-Behçet syndrome.
Garcia-Estrada C, Casallas-Vanegas A, Zabala-Angeles I, Gomez-Figueroa E, Rivas-Alonso V, Flores-Rivera J. Garcia-Estrada C, et al. Among authors: zabala angeles i. J Neuroimmunol. 2020 Jun 26;346:577308. doi: 10.1016/j.jneuroim.2020.577308. Online ahead of print. J Neuroimmunol. 2020. PMID: 32619893